Emergent Biosolutions Inc (NYSE:EBS) EVP Adam Havey sold 5,842 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $52.82, for a total value of $308,574.44. Following the transaction, the executive vice president now owns 35,756 shares in the company, valued at approximately $1,888,631.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Adam Havey also recently made the following trade(s):
- On Thursday, March 1st, Adam Havey sold 1,898 shares of Emergent Biosolutions stock. The shares were sold at an average price of $49.50, for a total value of $93,951.00.
Shares of Emergent Biosolutions stock opened at $54.39 on Thursday. The company has a current ratio of 4.85, a quick ratio of 3.42 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $2,660.33, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 1.05 and a beta of 1.26. Emergent Biosolutions Inc has a 12-month low of $27.94 and a 12-month high of $54.87.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.04. Emergent Biosolutions had a return on equity of 13.66% and a net margin of 14.73%. The firm had revenue of $193.80 million for the quarter, compared to analysts’ expectations of $189.96 million. During the same period in the previous year, the firm posted $0.74 EPS. The business’s revenue for the quarter was up 27.8% compared to the same quarter last year. equities research analysts anticipate that Emergent Biosolutions Inc will post 2.33 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Financial Gravity Companies Inc. bought a new stake in shares of Emergent Biosolutions in the 4th quarter worth approximately $118,000. IFG Advisory LLC bought a new stake in shares of Emergent Biosolutions in the 4th quarter worth approximately $1,050,000. LS Investment Advisors LLC boosted its position in shares of Emergent Biosolutions by 183.0% in the 4th quarter. LS Investment Advisors LLC now owns 3,948 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 2,553 shares in the last quarter. GW&K Investment Management LLC bought a new stake in shares of Emergent Biosolutions in the 4th quarter worth approximately $200,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Emergent Biosolutions in the 3rd quarter worth approximately $191,000. 81.54% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently issued reports on the company. Zacks Investment Research downgraded Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 19th. Goldman Sachs assumed coverage on Emergent Biosolutions in a research report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 price objective on the stock. Chardan Capital lifted their price objective on Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. ValuEngine raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Singular Research lifted their price objective on Emergent Biosolutions from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Emergent Biosolutions presently has an average rating of “Buy” and an average price target of $52.80.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.